메뉴 건너뛰기




Volumn 52, Issue 9, 2006, Pages 791-796

Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system;Prevence vzniku diabetu 2. Typu při léčbě antihypertenzivy ovlivňujícími systém renin-angiotenzin

Author keywords

ACE inhibitors; AT1 blockers; Diabetes mellitus; Hypertension; Insulin resistance; Renin angiotensin system; Risk factors

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; LISINOPRIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RAMIPRIL;

EID: 33749440597     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (4)

References (34)
  • 1
    • 24044536393 scopus 로고    scopus 로고
    • Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomised clinical trials
    • Abuissa H, Jones PG, Marso SP et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomised clinical trials. J Am Coll Cardiol 2005; 46: 821-826.
    • (2005) J Am Coll Cardiol , vol.46 , pp. 821-826
    • Abuissa, H.1    Jones, P.G.2    Marso, S.P.3
  • 2
    • 0344373794 scopus 로고    scopus 로고
    • Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    • ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Jama 2002; 288: 2981-2997.
    • (2002) Jama , vol.288 , pp. 2981-2997
  • 3
    • 1542547460 scopus 로고    scopus 로고
    • Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity
    • Benson S, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ- modulating activity. Hypertension 2004; 43: 993-1002.
    • (2004) Hypertension , vol.43 , pp. 993-1002
    • Benson, S.1    Pershadsingh, H.A.2    Ho, C.I.3
  • 4
    • 19644400972 scopus 로고    scopus 로고
    • Angiotensin-converting-enzyme inhibition in stable coronary artery disease
    • Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-2068.
    • (2004) N Engl J Med , vol.351 , pp. 2058-2068
    • Braunwald, E.1    Domanski, M.J.2    Fowler, S.E.3
  • 5
    • 33749433040 scopus 로고    scopus 로고
    • Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporuč ení českých odborných společností
    • Cífkova R, Býma S, Češka R et al. Prevence kardiovaskulárních onemocnění v dospě lém věku. Společné doporučení českých odborných společností. Vnitř Lék 2005; 51: 1021-1036.
    • (2005) Vnitř Lék , vol.51 , pp. 1021-1036
    • Cífkova, R.1    Býma, S.2    Češka, R.3
  • 6
    • 24644443331 scopus 로고    scopus 로고
    • Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial
    • Dahlof B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
    • (2005) Lancet , vol.366 , pp. 895-906
    • Dahlof, B.1    Sever, P.S.2    Poulter, N.R.3
  • 7
    • 0030034315 scopus 로고    scopus 로고
    • Potential role of bradykinin in forearm muscle metabolism in humans
    • Dietze GJ, Wicklmayr M, Rett K et al. Potential role of bradykinin in forearm muscle metabolism in humans. Diabetes 1996; 45 (Suppl 1): S110-S114.
    • (1996) Diabetes , vol.45 , Issue.SUPPL. 1
    • Dietze, G.J.1    Wicklmayr, M.2    Rett, K.3
  • 8
    • 5644250670 scopus 로고    scopus 로고
    • Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: The DREAM trial
    • Gerstein HC, Yusuf S, Holman R et al. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004; 47: 1519-1527.
    • (2004) Diabetologia , vol.47 , pp. 1519-1527
    • Gerstein, H.C.1    Yusuf, S.2    Holman, R.3
  • 9
    • 0034732256 scopus 로고    scopus 로고
    • Hypertension and antihypercensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study
    • Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypercensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905-912.
    • (2000) N Engl J Med , vol.342 , pp. 905-912
    • Gress, T.W.1    Nieto, F.J.2    Shahar, E.3
  • 10
    • 0034573433 scopus 로고    scopus 로고
    • Results of the STOP-hypertension-2 trial
    • Hansson L. Results of the STOP-hypertension-2 trial. Blood Press Suppl 2000; 2: 17-20.
    • (2000) Blood Press Suppl , vol.2 , pp. 17-20
    • Hansson, L.1
  • 11
    • 0033034404 scopus 로고    scopus 로고
    • Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPP) randomised trial
    • Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999; 353: 611-616.
    • (1999) Lancet , vol.353 , pp. 611-616
    • Hansson, L.1    Lindholm, L.H.2    Niskanen, L.3
  • 12
    • 0032767731 scopus 로고    scopus 로고
    • ACE inhibition and glucose transport in insulin resistant muscle: Roles of bradykinin and nitric oxide
    • Henriksen EJ, Jacob S, Kinnick TR et al. ACE inhibition and glucose transport in insulin resistant muscle: roles of bradykinin and nitric oxide. Am J Physiol 1999; 277: R332-R336.
    • (1999) Am J Physiol , vol.277
    • Henriksen, E.J.1    Jacob, S.2    Kinnick, T.R.3
  • 13
    • 18844449196 scopus 로고    scopus 로고
    • Why blockade of the reninangiotensin system reduces the incidence of new-onset diabetes
    • Jandeleit-Dahm K, Tikellis C, Reid CM et al. Why blockade of the reninangiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463-473.
    • (2005) J Hypertens , vol.23 , pp. 463-473
    • Jandeleit-Dahm, K.1    Tikellis, C.2    Reid, C.M.3
  • 14
    • 2942635317 scopus 로고    scopus 로고
    • Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial
    • Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
    • (2004) Lancet , vol.363 , pp. 2022-2031
    • Julius, S.1    Kjeldsen, S.E.2    Weber, M.3
  • 15
    • 18544376399 scopus 로고    scopus 로고
    • Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study
    • Lindholm LH, Ibsen H, Borch-Johnsen K et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-1886.
    • (2002) J Hypertens , vol.20 , pp. 1879-1886
    • Lindholm, L.H.1    Ibsen, H.2    Borch-Johnsen, K.3
  • 16
    • 0042154108 scopus 로고    scopus 로고
    • Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)
    • Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563-1574.
    • (2003) J Hypertens , vol.21 , pp. 1563-1574
    • Lindholm, L.H.1    Persson, M.2    Alaupovic, P.3
  • 17
    • 0037534905 scopus 로고    scopus 로고
    • The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomised double-blind intervention trial
    • Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21: 875-886.
    • (2003) J Hypertens , vol.21 , pp. 875-886
    • Lithell, H.1    Hansson, L.2    Skoog, I.3
  • 18
    • 0037410532 scopus 로고    scopus 로고
    • ACE inhibition may decrease diabetes risk by boosting the impact of bradykinin on adipocytes
    • McCarty MF. ACE inhibition may decrease diabetes risk by boosting the impact of bradykinin on adipocytes. Med Hypotheses 2003; 60: 779-783.
    • (2003) Med Hypotheses , vol.60 , pp. 779-783
    • McCarty, M.F.1
  • 19
    • 0345492460 scopus 로고    scopus 로고
    • A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial
    • Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816.
    • (2003) JAMA , vol.290 , pp. 2805-2816
    • Pepine, C.J.1    Handberg, E.M.2    Cooper-DeHoff, R.M.3
  • 20
    • 0042410539 scopus 로고    scopus 로고
    • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Overall programme
    • Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Overall programme. Lancet 2003; 362: 759-766.
    • (2003) Lancet , vol.362 , pp. 759-766
    • Pfeffer, M.A.1    Swedberg, K.2    Granger, C.B.3
  • 21
    • 4043117221 scopus 로고    scopus 로고
    • Diabetes and cardiovascular outcomes in elderly subjects treated with ACE-inhibitors or diuretics: Findings from the 2nd Australian National Blood Pressure Study
    • Reid CM, Jonston CI, Ryan P et al. Diabetes and cardiovascular outcomes in elderly subjects treated with ACE-inhibitors or diuretics: findings from the 2nd Australian National Blood Pressure Study. Am J Hypertens 2003; 16: A11.
    • (2003) Am J Hypertens , vol.16
    • Reid, C.M.1    Jonston, C.I.2    Ryan, P.3
  • 22
    • 2242475750 scopus 로고    scopus 로고
    • Účinnost a snášenlivost fosinoprilu v léčbě mírné a středně těžké arteriální hypertenze (Multicentrická prospektivní otevřená klinická studie)
    • Rosolová H, Čech J, Šefrna F. Účinnost a snášenlivost fosinoprilu v léčbě mírné a středně těžké arteriální hypertenze (Multicentrická prospektivní otevřená klinická studie). Vnitř Lék 2001; 47: 834-839.
    • (2001) Vnitř Lék , vol.47 , pp. 834-839
    • Rosolová, H.1    Čech, J.2    Šefrna, F.3
  • 23
    • 0036840307 scopus 로고    scopus 로고
    • Angiotensin blockade prevents type 2 diabetes by formation of fat cells
    • Sharma AM, Janke J, Gorzelniak K et al. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609-611.
    • (2002) Hypertension , vol.40 , pp. 609-611
    • Sharma, A.M.1    Janke, J.2    Gorzelniak, K.3
  • 24
    • 3142781955 scopus 로고    scopus 로고
    • Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system
    • Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004; 64: 2537-2565.
    • (2004) Drugs , vol.64 , pp. 2537-2565
    • Scheen, A.J.1
  • 25
    • 33644672013 scopus 로고    scopus 로고
    • Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity
    • Schupp M, Clemenz M, Gineste R et al. Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes 2005; 54: 3442-3452.
    • (2005) Diabetes , vol.54 , pp. 3442-3452
    • Schupp, M.1    Clemenz, M.2    Gineste, R.3
  • 26
    • 2442451618 scopus 로고    scopus 로고
    • Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity
    • Schupp M, Janke J, Classen R et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 2004; 109: 2054-2057.
    • (2004) Circulation , vol.109 , pp. 2054-2057
    • Schupp, M.1    Janke, J.2    Classen, R.3
  • 27
    • 0034732073 scopus 로고    scopus 로고
    • Antihypertensive therapy and the risk of type 2 diabetes mellitus
    • Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med 2000; 342: 969-970.
    • (2000) N Engl J Med , vol.342 , pp. 969-970
    • Sowers, J.R.1    Bakris, G.L.2
  • 28
    • 0010795476 scopus 로고    scopus 로고
    • Nateglinide and valsartan in impaired glucose tolerance outcomes research, rationale and design of the NAVIGATOR trial
    • The NAVIGATOR Trial Steering Committee. Nateglinide and valsartan in impaired glucose tolerance outcomes research, rationale and design of the NAVIGATOR trial. Diabetes 2002; 51 Suppl. 2: A116.
    • (2002) Diabetes , vol.51 , Issue.SUPPL. 2
  • 29
    • 3142740224 scopus 로고    scopus 로고
    • Rationale, design, and base-line characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials
    • The ONTARGET/TRANSCEND Investigators. Rationale, design, and base-line characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148: 52-61.
    • (2004) Am Heart J , vol.148 , pp. 52-61
  • 30
    • 1842475446 scopus 로고    scopus 로고
    • Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat
    • Tikellis C, Wookey PJ, Candido R et al. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004; 53: 989-997.
    • (2004) Diabetes , vol.53 , pp. 989-997
    • Tikellis, C.1    Wookey, P.J.2    Candido, R.3
  • 31
    • 0028213184 scopus 로고
    • Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: Bradykinin may improve insulin resistance in dogs and humans
    • Uehara M, Kishikawa H, Isami S et al. Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans. Diabetologia 1994; 37: 300-307.
    • (1994) Diabetologia , vol.37 , pp. 300-307
    • Uehara, M.1    Kishikawa, H.2    Isami, S.3
  • 32
    • 2342652390 scopus 로고    scopus 로고
    • Adverse prognostic significance of new diabetes in treated hypertensive subjects
    • Verdecchia P, Reboldi G, Angeli F et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-969.
    • (2004) Hypertension , vol.43 , pp. 963-969
    • Verdecchia, P.1    Reboldi, G.2    Angeli, F.3
  • 33
    • 0037432313 scopus 로고    scopus 로고
    • Enalapril reduces the incidence of diabetes in patients with chronic heart failure: Insight from the Studies of Left Ventricular Dysfunction (SOLVD)
    • Vermes E, Ducharme A, Bourassa MG et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107: 1291-1296.
    • (2003) Circulation , vol.107 , pp. 1291-1296
    • Vermes, E.1    Ducharme, A.2    Bourassa, M.G.3
  • 34
    • 0035904369 scopus 로고    scopus 로고
    • Ramipril and the development of diabetes
    • Yusuf S, Gerstein HC, Hoogwerf B et al. Ramipril and the development of diabetes. JAMA 2001; 286: 1882-1885.
    • (2001) JAMA , vol.286 , pp. 1882-1885
    • Yusuf, S.1    Gerstein, H.C.2    Hoogwerf, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.